Literature DB >> 498073

In vivo cell cycle synchronization of the murine sarcoma 180 tumor following alternating periods of hydroxyurea blockade and release.

K Tomita, J E Plager.   

Abstract

The durations of the cell cycle intervals of the murine Sarcoma 180 tumor were determined by computer analysis of the fraction-labeled mitosis curve following tritiated thymidine administration. This tumor has a usual total cell cycle duration of 19.6 hr, a DNA synthetic time of 8.3 hr, and a growth fraction of 1. Approximately 38% of cells are in S phase at one time. Hydroxyurea (HU) infusions (i.v.) at 1.17 mg/hr into tumor-bearing mice rapidly inhibit tumor DNA synthesis. Following a 5-hr HU infusion, 58% of all tumor cells are in S phase, and maximal tumor mitotic rates after release of the HU blockade are double control rates. HU was infused for 5 hr, followed by 7 hr of Ringer's solution, and then another 5 hr of HU. Following this 2-cycle blockade, 70% of tumor cells are in S phase, predominantly in early S phase and at the G1-S junction. After release, peak mitotic rates are 2.5 times control. The duration of the intermitotic time of the tumor following HU infusion is less than the total cell cycle time of control tumor. Cycles of HU infusion and release, timed according to the predetermined duration of the cell cycle intervals, will synchronize significant increments of S phase or mitotic cells of the Sarcoma 180 tumor during predictable periods of time.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498073

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Human tumor clonogenic assay in osteosarcoma for evaluation of clinical efficacy of anti-cancer drugs.

Authors:  K Tomita; A Yokogawa; S Nomura
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors.

Authors:  Andrea Sottoriva; Louis Vermeulen; Simon Tavaré
Journal:  PLoS Comput Biol       Date:  2011-05-05       Impact factor: 4.475

3.  Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma.

Authors:  Subhasis Das; Kaushik Kumar Dey; Goutam Dey; Ipsita Pal; Abhijit Majumder; Sujata MaitiChoudhury; Subhas C kundu; Mahitosh Mandal
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

4.  Determining duration of HER2-targeted therapy using stem cell extinction models.

Authors:  Lindsay Riley; Hua Zhou; Kenneth Lange; Janet S Sinsheimer; Mary E Sehl
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.